Uromitexan 400 mg

/ Megapharm

400 mg is usually administered by I.V. injection in adults at a dose of 20% of the respective oxazaphosphorine dose, at times 0 (administration of oxazaphosphorine), four hours and eight hours.
See prescribing information for full details.

Prevention of urinary passage toxicity of oxazaphosphorines (the active components of Holoxan, Ifosfamide , Endoxan, Cyclophosphamide, Ixoten, Trofosamide), in particular in high-risk patients with previous radiation therapy in the area of the lesser pelvis, cystitis with previous Holoxan, Endoxan or Ixoten, urinary passage diseases in anamnesis.

Known hypersensitivity to mesna, other thiol compounds, or any of the excipients.  

Autoimmune diseases are associated with an increased risk of allergic and/or anaphylactoid reactions. For that reason, protection of the urinary tract using this drug in such patients requires careful risk/benefit assessment and the supervision of a physician.
See prescribing information for full details

Nausea, vomiting, Itching, exanthema, reactions of the mucous membranes, Fever, Local oedema, Venous irritation at the injection site, chills.
See prescribing information for full details.

Treatment with this drug may cause false-positive reactions in tests for ketone bodies in the urine. However, the colour reaction is reddish purple rather than purple, less stable and fades immediately by adding glacial acetic acid.

This drug is used as uro-protector concurrently with cytostatic treatment with oxazaphosphorines, the criteria of these cytostatic therapies concerning use during pregnancy and lactation apply. Animal testing did not yield any evidence of embryotoxic or teratogenic effects of this drug.

No specific antidote for mesna is known. Concerning the anaphylactoid reactions see prescribing information for full details.

Storage: Store below 30°C, after reconstitution – store at 25°C up to 24 hours.